Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of Nuclear Medicine Sart Tilman B 35 4000 Liège The TITMaG project : a targeted and individualized treatment for malignant gliomas. (PNC_29_006) Département de medicine Service d Hematologie Domaine Universitaire du Sart Tilman B35 Mesenchymal stem cells (MSC) as prevention and treatment of graft-versus-host disease (GVHD) and graft rejection / poor graft function after allogenic hematopoietic cell transplantation (HCT). (PNC_29_007) Service d Hématologie Laboratoire de Thérapie Cellulaire et Génétique Domaine Universitaire du Sart Tilman B35 Tour 2 Niveau -3C
Characterization of molecular biomarkers relevant to the diagnosis and prognosis of peripheral T-cell lymphomas. (PNC_29_008) GIGA-Cancer Département de Pathologie Domaine Universitaire du Sart Tilman B23 Tour de Pathologie Role of the Wilms tumor gene product WT1 as biomarker for predicting relapse and for assessing the efficacy of dendritic cell vaccination in patients with hematological malignancies. (NKP_29_009) UZ Antwerpen Centrum voor celtherapie en regeneratieve geneeskunde Wilrijkstraat 10 2650 Edegem Biomarker based anti-egfr/her2neu treatment of lung cancer and overcoming resistance to anti-egfr therapies. (NKP_29_011) UZ Brussel Laarbeeklaan 101 1090 Brussels Improving the diagnostic and therapeutic management of patients with neuroblastoma by evaluation of mirna expression as a tool for outcome prediction and by targeted inhibition of ALK as a new treatment strategy. (NKP_29_014) Decreasing radiotherapy-induced side effects after breastconserving surgery. (NKP_29_015) Radiotherapie P7
Clinical translation of radio-labeled nanobodies for improved diagnosis and treatment of cancer. (NKP_29_016) UZ Brussel Nucleaire Geneeskunde Laarbeeklaan 101 1090 Brussels Safe margins in bone and soft tissue sarcomas : a prospective study. (PNC_29_018) Centre du Cancer B-cell chronic lymphocytic leukemia (B-CLL) : A model to test the synergy between chemotherapy and new biological treatments in an attempt to cure B-CLL patients. An interuniversity (UCL/KUL/AZBrugge/ULB) project. (PNC_29_019) Service d hématologie Cancer of the uterine cervix: an individualized therapeutic approach based on optimal prognostic evaluation. Potential impact on morbidity control. (PNC_29_022) Département de medicine Service d Hematologie Domaine Universitaire du Sart Tilman B35 Evaluation of the added value of functional imaging in a holistic molecular biomarker panel for therapy response in solid tumors : from imagination to image. (NKP_29_026) Internal Medicine HepatoGastroenterology Digestive Oncology Unit
Prospective clinical outcome of triple negative and basal like breast cancer in carriers of BRAC1 and BRAC2 mutations enrolled in the PACS 08 study. (PNC_29_027) Grand Hôpital de Charleroi Oncology-Hematology-Radiotherapy department Grand rue 3 6000 Charleroi Improvement of risk-based treatment stratification in childhood acute lymphoblastic leukemia by optimization of PCR-based minimal residual disease monitoring and identification of a mirna signature with possible prognostic value. (NKP_29_029) Ped. Haemato-Oncology and Stem Cell Transplantation Herpesvirus genotyping and phenotyping for the adjustment of antiviral chemotherapy in immunocompromised cancer patients. (NKP_29_032) Can response to epidermal growth factor receptor antibodies in patients with metastatic colorectal cancer be predicted? Advanced bio-informatics tools, integrating gene mutation and microarray data may hold the key. (NKP_29_034) High-throughput parallel sequencing for molecular diagnosis of cancer. (NKP_29_035) Implementation of functional imaging and molecular diagnostics for patient-tailored treatment of prostate cancer. (NKP_29_037)
Cancer during pregnancy : a clinico-pharmacologic study. (NKP_29_038) Genetic signatures for the prediction of platinium-sensitivity in ovarian cancer. (NKP_29_039) Patient-tailored treatment for rectal cancer. (NKP_29_045) Characterization of spontaneous and vaccine-induced immune responses against melanoma, and analysis of their influence on the clinical course of the patients. (PNC_29_049) Centre du Cancer Functional image-guided Intensity Modulated Therapy: integration of tumor microenvironment in treatment planning : a joint KUL-UCL project. (PNC_29_051) Centre du Cancer Genetic and epigenetic characterization of breast cancer using ultra deep sequencing analysis : A step towards the individualization of breast cancer patient treatment. (PNC_29_055)
Tumor receptor imaging combined with early metabolic response assessment : a promising approach for evaluating targeted treatment in oncology. An interuniversity (ULB-VUB-UZA) project. (PNC_29_056) New Approaches for defining prognostic factors in B-lineage acute lymphoblastic leukemia (ALL): study of the immune microenvironment using immunophenotypic and genomic methodologies, and of the leukemic blasts proteomic and interactomic profile. (PNC_29_058) Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer : PePiTA trial. (PNC_29_059) Biological factors predicting response to chemotherapy in advanced non small cell lung cancer : a prospective study. (PNC_29_060)